[1] Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J, 2009, 122(1):1-2. [2] Goldstein ST, Zhou F, Hadle SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact[J]. Int J Epidemiol, 2005, 34(6):1329-1339. [3] Guha C, Mohan S, Roy-Chowdhury N, et al. Cell culture and animal models ofviral hepatitis. Part I:hepatitis B[J]. Lab Anim, 2004, 33(7):37-46. [4] Nassal M, Dallmeier K, Schultz U, et al. Phenotyping hepatitis B virus variants:fromtransfection towards a small animal in vivo infection model[J]. J ClinVirol, 2005, 34(Suppl 1):S89-S95. [5] 冯广义, 张养生. 乙型肝炎病毒感染模型研究进展[J]. 中华 实验和临床感染病杂志, 2009, 3(3):329-333. [6] 王选举, 黄正明, 宋建国. 乙型肝炎病毒感染模型的研究进 展[J]. 传染病信息, 2009, 2(3):189-192. [7] 卢渝, 张君. 乙型肝炎病毒感染模型的研究进展[J]. 中外医 疗, 2009, 27:172-174. [8] Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracylines in mammalian cells[J]. Science, 1995, 268(5218): 1766-1769. [9] 蔡大伟, 侯艳. 原代肝细胞培养技术研究现状及其新药研发中 的应用[J]. 解放军药学学报, 2009, 25:245-246. [10] Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry[J]. World J Gastroenterol, 2007, 13(1): 22-38. [11] 姚永远, 马立宪, 赛林涛, 等. 新型乙型肝炎病毒细胞感染模 型的建立[J]. 世界华人消化杂志, 2010, 18(8):755-760. [12] Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells:a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics[J]. Chem-Biol Interact, 2007, 168(1):66-73. [13] 陈豪, 李丹, 林纳, 等. 乙肝病毒X 基因慢病毒载体的构建和 鉴定[J]. 福建医科大学学报, 2011, 45(3):187-191. [14] Escors D, Breckpot K. Lentiviral vectors in gene therapy:Their current status and future potential[J]. Arch Immunol Ther Exp, 2010, 58:107-119. |